Oral combination chemotherapy in the treatment of AIDS-associated Hodgkin's disease

East African Medical Journal

Volumn 82, Issue 9 SUPPL., 2005, Pages

  Orem, J ^a,f   Fu, P ^b,c,d   Ness, A ^c   Mwanda, W O ^e   Remick, S C ^b,c,d  

^a MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^e UNIVERSITY OF NAIROBI   (Kenya)

^f UGANDA CANCER INSTITUTE   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ETOPOSIDE; LOMUSTINE; PROCARBAZINE;

ADULT; ARTICLE; B CELL LYMPHOMA; CLINICAL TRIAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; MALE; MIDDLE AGED; MORTALITY; PHASE 2 CLINICAL TRIAL; SURVIVAL;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYCLOPHOSPHAMIDE; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; LOMUSTINE; LYMPHOMA, AIDS-RELATED; MALE; MIDDLE AGED; PROCARBAZINE; SURVIVAL ANALYSIS;

EID: 33744477922     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Hessol, N. A., Katz, M. H., Liu, J. Y., Buchbinder, S. P., Rubino, C. J., and Holmberg, S. D. Increased incidence of Hodgkin's disease in homosexual men with HIV infection. Ann. Intern. Med. 1992; 117:309-311.
2. Lyter, D. W., Bryant, J., Thackeray, R., Rinaldo, C. R., and Kingsley, L. A. Incidence of human immunodeficiency virus-related and non related malignancies in a large cohort of homosexual men. J. Clin. Oncol. 1995; 13:2540-2546.
3. Grulich, A. E., Li, Y., McDonald, A., Correll, P. K., Law, M.G. and Kaldor, J. M. Rates of non-AIDS defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002; 16:1155-1161.
4. Frisch, M., Biggar, R. J., Engels, E. A. and Goedert, J. J. for the AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression-in adults. J. Amer. Med. Ass. 2001; 285:1736-1745.
5. Tirelli, U., Errante, D., Dolcetti, R., Gloghini, A. et al. Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J. Clin. Oncol. 1995; 13:1758-1767.
6. Levine, A. M. Hodgkin's disease in the setting of human immunodeficiency virus infection. J. Natl. Cancer Inst. Monogr. 1998; 23:37-42.
7. Levine, A. M. HIV-associated Hodgkin's disease. Biologic and clinical aspects. Hematol Oncol. Clin. North. Am. 1996; 10:1135-1148.
8. Herndier, B. G., Sanchez, H. C., Chang, K. L., Chen, Y. Y. and Weiss, L. M. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of HIV-associated Hodgkin's disease. Amer. J. Pathol. 1993; 142:1073-1079.
9. Audouin, J., Diebold, J. and Pallesen, G. Frequent expression of Epstein-Barr virus latent membrane protein-1 in tumour cells of Hodgkin's disease in HIV-positive patients. J. Pathol. 1992; 167:381-384.
10. Re, A., Casari, S., Cattaneo, C. et al. Hodgkin disease developing in patients infected by human immunodeficiency virus results in clinical features and a prognosis similar to those in patients with human immunodeficiency virus-related non Hodgkin Lymphoma. Cancer 2001; 92:2739-2745.
11. Spina, M., Berretta, M. and Tirelli, U. Hodgkin's disease in HIV. Hematol. Oncol. Clin. N. Amer. 2003; 17:843-858.
12. Errante, D., Gabarre, J., Ridolfo, A. L. et al. Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF. Ann. Oncol. 1999; 10:189-195.
13. Otieno, M. W., Banura, C., Katongole-Mbidde, E. et al. Therapeutic challenges of AIDS-related non-Hodgkin's Lymphoma in the United States and East Africa. J. Natl. Cancer. Inst. 2002;94:718-732.
14. Remick, S. C., Sedransk, N., Haase, R. F. et al. Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's Lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up. Amer. J. Hematol. 2001; 66:178-188.
15. Remick, S. C., McSharry, J. J., Wolf, B. C. et al. Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's Lymphoma. J. Clin. Oncol. 1993; 11:1691-1702.
16. Remick, S. C., Sedransk, N., Haase, R. et al. Oral combination chemotherapy in the management of AIDS-related Lymphoproliferative malignancies. Drugs. 1999; 58(Suppl 3):99-107.
17. O'Dwyer, P. F., Leyland-Jones, B., Alonso, M. T., Marsoni, S. and Wittes, R. E., Etoposide (VP-16-213). Current status of an active anticancer drug. N. Engl. J. Med. 1985; 312:692-700.
18. Wiernik, P. H. Chemotherapy for Hodgkin's disease. In: Updates: Cancer. Principles and Practice of Oncology. DeVita V. T. Jr, Hellman S., and Rosenber S. A. (eds.). New York: Lippincott, Williams and Wilkins. 1988; 2:1-12.
19. DeVita, V. T. Jr., Simon, R. M., Hubbard, S. M. et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann. Intern. Med. 1980; 92:587-595.
20. Bakemeier, R. F., Anderson, J. R., Costello, W. et al. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity that with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study. Ann. Intern. Med. 1984; 101:447-456.
21. Buzaid, A. C., Lippman, S. M. and Miller, T. P. Salvage therapy of advanced Hodgkin's disease. Critical appraisal of curative potential. Amer. J. Med. 1987; 83:523-532.
22. Burchenal, J. H., Lokys, L., Turkevich, J. and Gale G. Rationale of combination chemotherapy. In: Cisplatin: Current Status and New Developments. Prestayko A. W., Crooke, S. T. and Carter, S. K. (eds.). New York: Academic Press. 1980; 1:13-23.
23. Garber, E. K., Fan, P. T. and Bluestone, R. Realistic guidelines of corticosteroid therapy in rheumatic disease. Semin Arthrits Rheum 1981; 11:231-256.
24. Struck, A. E. Minder, C. E. and Frey, F. J. Risk of infectious complications in patients taking glucocortisteroids. Rev. Infect. Dis. 1989; 11:954-963.
25. Gill, P. S., Loureiro, C., Bernstein-Singer, M., Rarick, M. U., Sattler, L. and Levine A. M. Clinical effect of glucocorticoids on Kaposi's sarcoma related to the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 1989; 110:937-940.
26. Real, F. X., Krown, S. E. and Koziner, B. Steroid-induced development of Kaposi's sarcoma in a homosexual man with Burkitt's Lymphoma. Amer. J. Med. 1986; 80:119-122.
27. Schulhafer, E. P., Grossman, M. E., Fagin, G. and Bell, K. E. Steroid induced Kaposi's sarcoma in a patient with pre-AIDS. Amer. J. Med. 1987; 82:313-317.
28. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome for national reporting - United States. Morbid Mortal Weekly Rep. 1987; 36(Suppl 1):1-15.
29. Oken, M. M., Creech, R. H., Tormey, D. C. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Amer. J. Clin. Oncol. 1982; 5:649-655.
30. National Cancer Institute. Common Toxicity Criteria, version 2.0. Bethesda, MD, NCI. 1999.
31. Kaplan, E. L. and Meier, P. Nonparametric estimation from incomplete observations. J. Amer. Stat. Assoc. 1958; 53: 457-481.
32. Tirelli, U., Errante, D., Dolcetti, R. et al. Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J. Clin. Oncol. 1995; 13:758-767.
33. Rubio, R. for the Cooperative Study Group of Malignancies associated with HIV infection of Madrid. Hodgkin's disease associated with human immunodeficiency virus infection. A clinical study of 46 cases. Cancer. 1994; 73:2400-2407.
34. Serrano, M., Bellas, C., Campo, E. et al. Hodgkin's disease in patients with antibodies to human immunodeficiency virus. A study of 22 patients. Cancer. 1990; 65:2248-2254.
35. Errante, D., Tirelli, U., Gastaldi, R. et al. for the Italian Cooperative Group on AIDS and Tumors (GICAT). Combined antineoplastic and antiretroviral therapy for patients with Hodgkin's disease and human immunodeficiency virus infection. A prospective study of 17 patients. Cancer. 1994; 73:437-444.
36. Spina, M., Gabarre, J., Rossi, G. et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin's disease and HIV infection. Blood. 2002; 100:1984-1989.
37. Hasenclever, D., Diehl, V., Armitage, J. O. et al. for the International Prognostic Factors Project on Advanced Hodgkin's Disease. A prognostic score for advanced Hodgkin's disease. N. Engl. J. Med. 1998; 339:1506-1514.
38. Orem, J., Otieno, M. W., Fu, P. et al. Effects of oral chemotherapy on CD4 Lymphocyte count and HIV-1 plasma RNA (VL) in patients with AIDS-related nonHodgkin's Lymphoma (AR-NHL) in East Africa as part of a clinical trial. Poster presentation at the 8th International Conference on Malignancies in AIDS and Other Immunodeficiencies, NIH, Bethesda, MD, April 29-30, 2004 (Abstract nos. 48).